重组人血管内皮抑制素联合顺铂腹腔灌注治疗卵巢癌腹腔积液的临床观察

Clinical Observation of Recombinant Human Endostatin Combined with Cisplatin Peritoneal Perfusion in the Treatment of Malignant Ascites of Ovarian Cancer

目的:探讨重组人血管内皮抑制素联合顺铂腹腔灌注治疗卵巢癌的近期疗效、毒副反应及患者的耐受性。方法:52例卵巢癌合并腹腔积液患者采用随机数字表法分为试验组和对照组,试验组30例,对照组22例;3例患者失访(其中试验组2例,对照组1例),5例患者未完成治疗计划(试验组4例,对照组1例)。试验组采用方案:重组人血管内皮抑制素(60 mg第1、8、15天)联合顺铂(75 mg/m^2第1天)腔内灌注同时紫杉醇(135 mg/m^2第1天)静脉输注。对照组采用方案:紫杉醇(135 mg/m^2第1天)静脉输注同时顺铂(75 mg/m^2第1天)腔内灌注。两组均治疗6个周期。结果:两组近期有效率:试验组为87.5%,对照组为50.0%,两组比较差异有统计学意义(P<0.05);但在窦性心动过速、Ⅱ~Ⅲ级腹痛和Ⅱ~Ⅲ级肝功能损害方面,试验组均高于对照组,差异均有统计学意义(P<0.05),白细胞减少、血红蛋白减少及恶心呕吐等发生率两组比较,差异均无统计学意义(P>0.05)。结论:重组人血管内皮抑制素联合顺铂腹腔灌注治疗卵巢癌腹腔积液的近期疗效肯定、安全性高,患者的耐受性好。

Objective:To investigate the recent efficacy,toxicity and tolerance of Recombinant Human Endostatin combined with Cisplatin peritoneal perfusion in the treatment of malignant ascites of ovarian cancer.Method:A total of 52 patients with malignant ascites of ovarian cancer were divided into the experimental group(n=30)and the control group(n=22)by randomization method.Three patients lost their follow-up(2 cases in the experimental group,1 case in the control group),and 5 patients did not complete the treatment plan(4 cases in the experimental group and 1 case in the control group).The experimental group adopted Recombinant Human Vascular Endostatin(60 mg,d1,d8,d15)combined with Cisplatin(75 mg/m2d1)peritoneal perfusion and Paclitaxel(135 mg/m2,d1)intravenous infusion.The control group given Paclitaxel(135 mg/m2,d1)intravenous infusion,Cisplatin(75 mg/m2 d1)peritoneal perfusion.Two groups were both given 6 cycles.Result:The recently effective rate of the experimental group was 87.5%,and the control group was 50.0%,and the difference was statistically significant(P<0.05).But in sinus tachycardia,Ⅱ-Ⅲgrade abdominal pain andⅡ-Ⅲgrade liver function damage,the experimental group were higher than those of the control group(P<0.05),white blood cells reduce,hemoglobin and the incidence of nausea and vomiting,real differences between two groups had no statistical significance(P>0.05).Conclusion:The recent efficacy and safety of Recombinant Human Endostatin combined Cisplatin peritoneal perfusion in the treatment of malignant ascites of ovarian cancer are high,and the patient’s lerance is good.